Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Phase II Clinical Trial

Next Previous
X
Search
Trial Profile

Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Phase II Clinical Trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DB-001 (Primary)
  • Indications Adult respiratory distress syndrome; COVID 2019 infections; COVID-19 respiratory infection
  • Focus Therapeutic Use
  • Acronyms EXIT COVID-19
  • Sponsors Direct Biologics

    • Most Recent Events

    • 12 Jul 2023 According to a Direct Biologics media release, results were published in the June 2023 edition of the peer-reviewed medical journal CHEST.
    • 12 Jul 2023 Results published in a Direct Biologics Media Release.
    • 14 Mar 2023 According to a Direct Biologics media release, On review by an independent data safety monitoring board (DSMB), no AEs or SAEs were determined to be related to ExoFlo.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top